NEW MEDICINE PARTNERS

We are an advisory company that creates strategies for precision medicine health to advance healthy lifespan, utilising power of AI to target and personalise. We work with government agencies, investors, public and private health service providers, SMEs, start-ups, and research organisations.

Healthspan / Longevity Clinic Advisory Services

We advise newly established clinics on product / client strategy, regulatory requirements, equipment, capacity and operational planning and utilisation management, and provide tailored support to existing aesthetic clinics wishing to expand into healthy longevity-focused establishments.

Longevity Technology Transfer and Commercialisation

We advise technology developers on market positioning, business case, value behind a longevity or preventative health technology and facilitate strategic partnerships for development and exit. We help technology adopters - investors and businesses - to discover early-stage longevity products with long-term market potential.

HEALTH SYSTEM OPTIMISATION FOR HEALTHY LONGEVITY

We advise on adaptation of national, provider and payor strategies for healthy longevity and care pathways. We specialise in personalised healthspan programmes, using AI tools for population analysis for early intervention and clinical decision making, and strategies for engagement of patients and clinicians.

Healthy longevity

Healthy longevity, or healthspan, is the one goal that unites all of humanity. Living longer is desirable only if the years gained are spent in good health. Who would not want to stay healthy for as long as possible? We now have the insight and technology to make it a reality. Preventative healthcare can bring in healthy longevity for all if we invest in precision population health, democratise access to health services and digital tools, and use emerging technology efficiently.

The rapidly growing longevity market offers financial rewards - increasing spending on preventative healthcare by 0.1% can unlock 9% increase in economic contribution. By preventing or postponing chronic disease and promoting healthy ageing we can all reap the benefits of living longer and happier lives.

We focus Healthy longevity, or healthspan
$26 bn
Size of the global longevity
market (2023)
$27 tn
The value to society of 1 year increase in healthspan (2023)
Our Purpose
We work with leading organisations to advance the state of disease prevention and the products of longevity science and their translation into practical application.
Our Mission
To bring the most promising preventative health technologies to the market and maximise their impact to the society and the individual.
Our Values
Imagination, ambition and expertise - applied responsibly. Healthspan is more important than lifespan. Prevention is better than cure.

Why US?

We are a highly experienced team with a wide ranging expertise from national policy and strategy to technology transfer and technology assessment to AI development and implementation for predictive healthcare. Our industry experience, technical knowledge and relationships within the healthcare sector brings value to organisations at every phase of their technology development. We facilitated market entry of innovative technologies in the UK, EU, North America, and Asia Pacific. We do not outsource any of our work and do not employ junior analysts; if you work with us you will get expert knowledge, disruptive thinking and tailored engagement to the needs of your project.

Past Projects

The Royal Society of Medicine

The Royal Society of Medicine: New Medicine Partners will support the development of an innovation strategy for the Royal Society of Medicine. A key goal is to enable the NHS to benefit from the onrush of AI and digital innovation, adding value to innovators in digital health, medical devices and biopharmaceuticals. The RSM is in a unique position to tackle one of the most persistent challenges in UK healthcare.

Kemijski Institut, National Institute of Chemistry (NIC)
Slovenia

New Medicine Partners is providing advisory services to Kemijski Institut, Slovenia. NMP will assist Kemijski Institut in development and internationalisation of their novel cell and gene therapies.

Kent Surrey Sussex Academic Health Science Network

New Medicine Partners is providing advisory services to Kent Surrey Sussex Academic Health Science Network. NMP will assist KSS AHSN in developing a commercial model for the Accelerated Medicines Digital Design Studio as a part of the bid for consortium funding.

Naturalworks

NMP is assisting this UK-based startup company in assessing the potential of CBD oil in health, wellness and longevity applications with the focus on cancer and arthritis.

Veratrak

NMP is assisting this UK-based startup company in using its technology to revolutionise pharmaceutical supply chains including COVID-19 and cell and gene therapies.

Linkedin Feed

New Medicine Partners
🧠 Revolutionizing Brain Health NeuroAge Therapeutics unveils a groundbreaking test that predicts dementia risk up to 30 years in advance—paving the way for earlier interventions and improved brain health! Learn more: https://lnkd.in/djNw8Y4T #BrainHealth #DementiaPrevention #MedicalInnovation
New Medicine Partners
Type 2 Diabetes and Brain Health: New Insights Fascinating research by Prenuvo highlights how MRI-based predictions of brain volume loss in Type 2 diabetes patients are independent of visceral fat distribution. A breakthrough in understanding the link between diabetes and brain health! Read more here: https://lnkd.in/drMnZh23 #DiabetesResearch #BrainHealth #MedicalImaging #MRI
New Medicine Partners
GLP-1RAs: Beyond Diabetes & Obesity Treatment New research systematically evaluates the broad health impacts of GLP-1 receptor agonists (GLP-1RAs), revealing reduced risks of neurocognitive, cardiometabolic, and infectious disorders—but also increased risks of gastrointestinal and kidney-related issues. A crucial step in understanding the benefits and risks of GLP-1RAs for better clinical care and research! Read the study here: https://lnkd.in/gfbR-Ytd #DiabetesCare #GLP1RA #HealthOutcomes #MedicalResearch
New Medicine Partners
Muvon Therapeutics reports positive interim Phase II results for their muscle precursor cell therapy for SUI and will present at the 2025 J.P. Morgan Healthcare Conference—a major leap for regenerative medicine! 🌟 At NMP, we thrive on such breakthroughs, driving innovation in biotech and longevity. Learn more: https://lnkd.in/dQeqdDsF #Longevity #Biotech #Innovation
New Medicine Partners
🚀 Groundbreaking advancements in age reversal and longevity! Telomir Pharmaceuticals’ latest preclinical study with Telomir-1 demonstrates confirmed age reversal, increased longevity, and improved healthspan. This innovation marks a significant step toward transforming healthcare and extending healthy living. At New Medicine Partners, we are inspired by such breakthroughs that align with our mission to drive progress in longevity and health technologies. 👉 Read the full article here: https://lnkd.in/epikDUNH #Longevity #AgeReversal #Innovation #Healthspan #NMP
New Medicine Partners
Exciting breakthrough in longevity science! Researchers have developed a treatment that reverses multiple hallmarks of aging, paving the way for healthier and longer lives. Read more: https://lnkd.in/debm2sXe
New Medicine Partners
🚀 Advancing Longevity Science Arda Therapeutics has secured $43M in Series A funding to push forward their innovative targeted cell depletion therapies for chronic diseases. This milestone underscores the growing momentum in longevity-focused biotech! At New Medicine Partners, we specialize in helping innovative longevity companies like Arda commercialize their technologies and secure funding. 🌐💡 If you're working on transformative health and longevity technologies, let’s connect and take your innovation to the next level. 👉 https://www.newmedicine.io Read more about Arda’s breakthrough here: https://lnkd.in/eCb_fNzv #Longevi...
New Medicine Partners
🌟 Exciting New Resource for Biomedical Research! 🌟 A Comprehensive Atlas of Proteome-Phenome Associations is now available! This groundbreaking work systematically maps 2,920 plasma proteins to the presence and onset of 720 diseases and 986 health-related traits, utilizing data from 53,026 individuals in the UK Biobank. This powerful resource holds the potential to accelerate discoveries in precision medicine and targeted therapies. Dive deeper into the details and explore the atlas here: https://lnkd.in/dr4Ba2BZ Read the full paper in Cell: https://lnkd.in/dA7qGeyN Kudos to the researchers behind this incredible contr...

“Richard Barker has been instrumental in guiding our early stage business through critical phases of growth. His deep expertise and strategic insights into the Life Sciences Industry have proven invaluable. Richard not only provided us with a comprehensive understanding of market trends and dynamics but also offered actionable advice on refining our product offering to better meet industry demands. We are grateful for Richard's unwavering support, guidance, and invaluable contributions to our journey. His dedication to empowering early stage businesses in the Life Sciences sector makes him not just a consultant but a true partner in our success.”

Jason Lacombe, CEO of Veratrak

“I worked with Olga Shvarova on a project, which exemplified the transformative potential of combining digital technology with life sciences and reducing barriers for innovation. From day one, Olga demonstrated a deep understanding of the intricate challenges of the project and quickly unraveled the complexities of the project and delivered a commercial strategy that brought clarity to our vision. She brought clarity and rigor to an incredibly complex project and her ability to transform visionary ideas into a structured, actionable commercial model set the foundation for everything we’ve achieved since. Olga didn’t just help us plan for success - she prepared us to thrive in the long term."

Melissa Ream, AI Adviser of Kent Surrey Sussex Academic Health Science Network (KSS AHSN),
now known as Health Innovation KSS

“Olga Shvarova helped us to understand the market potential, regulatory pathways, and to identify the value proposition that formed the foundation of our commercial strategy. She facilitated the introductions that led to academic partnerships for the development of our novel
micelle solution, which significantly accelerated our technology development efforts.
We are grateful for the support we received at the early stage before the larger in-house team was assembled as well as the feedback and strategic recommendation on IPR protection and in-licensing options which helped us to make informed decisions early on.”

Filipp Korentsvit, CEO of NaturalWorks, now NWPharma Ltd

Partner Organisations